NCT01531569

Single Oral Dose of BeneFlax to Healthy Young and Older Adults

Community Alliance for Quality of Life in Long Term Care: Single Oral Dose of BeneFlax to Healthy Young and Older Adults

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: University of Saskatchewan · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This study is being done to look at age differences in the way the investigators bodies break down a compound found in flax seed (secoisolariciresinol diglucoside or SDG). It is administered to research subjects in a product called BeneFlax, which a concentrated version of flax seed containing 38% SDG. It is known that as people age, their bodies undergo physical changes both on the outside and the inside. The aging process may change the way that the investigators bodies deal with compounds the investigators eat. As an important measure of safety, the investigators want to check for evidence whether there is a difference in break down of SDG between different age groups.

Conditions

• Diabetes Mellitus, Type 2
• Hypercholesterolemia

Interventions

Type	Name	Description
OTHER	BeneFlax - 38% secoisolariciresinol diglucoside (SDG)	0.8g of BeneFlax (contains 300mg SDG) given once by mouth

Timeline

• Start date: 2011-12-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2012-02-13
• Last updated: 2016-10-26

Locations

1 site across 1 country: Canada